Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
545.86B
Market cap545.86B
Price-Earnings ratio
26.21
Price-Earnings ratio26.21
Dividend yield
2.29%
Dividend yield2.29%
Average volume
7.60M
Average volume7.60M
High today
$232.30
High today$232.30
Low today
$226.54
Low today$226.54
Open price
$230.64
Open price$230.64
Volume
12.16M
Volume12.16M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$149.04
52 Week low$149.04

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $226.79, with a market capitalization of 545.86B. The stock trades at a price-to-earnings (P/E) ratio of 26.21 and offers a dividend yield of 2.3%.

During the trading session on 2026-05-16, Johnson & Johnson(JNJ) shares reached a daily high of $232.30 and a low of $226.54. At a current price of $226.79, the stock is +0.1% higher than the low and still -2.4% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 12.16M, versus its average volume of 7.6M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $149.04.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $149.04.

JNJ News

CNBC 4h
Why J&J thinks its new psoriasis pill could be one of its biggest drugs ever - CNBC

...

Why J&J thinks its new psoriasis pill could be one of its biggest drugs ever - CNBC
Simply Wall St 17h
Assessing Johnson & Johnson Valuation After Earnings Beat Guidance Hike And Ongoing Dividend Growth

Johnson & Johnson (JNJ) just reported quarterly earnings and sales ahead of expectations, supported by both its Innovative Medicines and MedTech segments, while...

Assessing Johnson & Johnson Valuation After Earnings Beat Guidance Hike And Ongoing Dividend Growth
24/7 Wall St. 24h
If You Have $480,000 Saved at 67 and Just Sold a Restaurant for $1.1 Million Cash, Here Is the Income Plan That Actually Holds

If You Have $480,000 Saved at 67 and Just Sold a Restaurant for $1.1 Million Cash, Here Is the Income Plan That Actually Holds By Drew Wood Published May 15, 1...

If You Have $480,000 Saved at 67 and Just Sold a Restaurant for $1.1 Million Cash, Here Is the Income Plan That Actually Holds

Analyst ratings

63%

of 27 ratings
Buy
63%
Hold
29.6%
Sell
7.4%

More JNJ News

Simply Wall St 2d
How Investors Are Reacting To Johnson & Johnson Expanding Its Coronary Lithotripsy Device Portfolio

Earlier this week, Johnson & Johnson’s Shockwave Medical unit launched the Shockwave C2 Aero coronary intravascular lithotripsy catheter globally, offering impr...

How Investors Are Reacting To Johnson & Johnson Expanding Its Coronary Lithotripsy Device Portfolio
Simply Wall St 3d
Johnson And Johnson’s C2 Aero Launch And What It Means For Valuation

Johnson & Johnson (NYSE:JNJ) has globally launched its next generation Shockwave C2 Aero coronary intravascular lithotripsy catheter. The device introduces new...

Johnson And Johnson’s C2 Aero Launch And What It Means For Valuation
24/7 Wall St. 3d
Russell 1000 Dividend ETF Hits $125 as Johnson & Johnson Leads The Safety Test

Russell 1000 Dividend ETF Hits $125 as Johnson & Johnson Leads The Safety Test By John Seetoo Published May 13, 9:01AM EDT Quick Read ONEY’s largest holdings—...

Russell 1000 Dividend ETF Hits $125 as Johnson & Johnson Leads The Safety Test
TipRanks 3d
Leerink upgrades J&J to Outperform on new drug momentum

Leerink upgraded Johnson & Johnson to Outperform from Market Perform with a price target of $265, up from $252. The firm says the company’s “strong new drug mom...

24/7 Wall St. 3d
The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio

The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio By Trey Thoelcke Published May 13, 8:15AM EDT Quick Read S&...

The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio
TipRanks 3d
Johnson & Johnson upgraded to Outperform from Market Perform at Leerink

Leerink analyst David Risinger upgraded Johnson & Johnson to Outperform from Market Perform with a $265 price target Published first on TheFly – the ultimate s...

TipRanks 4d
Johnson & Johnson announces global launch of Shockwave C2 Aero catheter

Johnson & Johnson announced the global launch of its Shockwave C2 Aero Coronary IVL Catheter designed for improved deliverability, enhanced lesion crossing and...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.